Navigation Links
Lance Armstrong through a physiological lens: hard training boosts muscle power 8%

if some major physiological changes happened, but here's a real quantified example."

He added: "Generally there are two ways to improve efficiency: Train your maximum capacity to be very high, or train your sub-maximal capacity to be very efficient. In Armstrong's case, he did both. In the lab they measured his performance against standard oxygen consumption and by the end of the study he was much more efficient utilizing the same amount of oxygen. But on the road," he pointed out, "it means he can go faster and get more guys off his wheel."

Effect of cancer, therapy nil

The period that started when Armstrong was 21 and just turning professional and ending at age 28 with his first TdF victory, also included his cancer diagnosis, surgery, chemotherapy and recovery. About eight months after chemotherapy ceased (August 1997), Armstrong was tested in Coyle's laboratory in the same manner as in his other four visits. The results showed that he "displayed no ill-effects from his previous surgeries and chemotherapy" and were in line with measurements expected from highly trained athletes during periods of detraining, Coyle added later.

The study notes that these findings could be "important because it provides insight, although limited, regarding the recovery of 'performance physiology' after successful treatment for advanced cancer."

Muscular efficiency through possible fiber change: making it look easy

Coyle concedes in the study that the "physiological mechanisms responsible for the 8% improvements in (muscle) efficiency when cycling, as well as the stimuli that provided this adaptation, are unclear. The observation that both gross and delta efficiency improved to the same extent and also with the same time course suggests an improved efficiency of ATP turnover within muscle fibers during contraction." (ATP, or adenosine triphosphate, is a nucleotide present that serves as an energy source for many metabolic processes.)'"/>

Source:American Physiological Society


Page: 1 2 3 4 5 6

Related biology news :

1. Termites feed through good vibrations
2. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
5. BRCA1 causes ovarian cancer through indirect, biochemical route
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
8. HIV-1 spread through six transmission lines in the UK
9. MUHC researchers make cancer target breakthrough
10. Breakthrough isolating embryo-quality stem cells from blood
11. Breakthrough System for Understanding Ocean Plant Life Announced
Post Your Comments:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... drinking water in Bangladesh called the "largest mass ... Health Organization and known to be responsible for a ... to have an immediate and toxic effect on the ... is the first to identify a dramatic present-day consequence ...
... HARBOR, N.Y. (Nov. 30, 2010) -- The nucleus of ... DNA replication, transcription, and RNA processing take place. Within the ... according to the functional demands of the cell. "The ... is arguably one of the most exciting fields of contemporary ...
... For Immediate Release A team of scientists from The ... in the body,s response to eliminate pathogens, such as bacteria ... field of immunology and have potential implications for far-ranging topics ... autoimmunity. The results of the study, led by Scripps ...
Cached Biology News:Arsenic-polluted water toxic to Bangladesh economy 2Arsenic-polluted water toxic to Bangladesh economy 3Arsenic-polluted water toxic to Bangladesh economy 4Scripps Research scientists redefine the role of plasma cells in the immune system 2Scripps Research scientists redefine the role of plasma cells in the immune system 3Scripps Research scientists redefine the role of plasma cells in the immune system 4
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... Piper Jaffray Health Care Conference on Tuesday, November 30, ...
... Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Biology Technology:HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: polystyrene flat ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
Biology Products: